Kaiser Foundation Hospitals

Kaiser Foundation Hospitals, operating through its Kaiser Foundation Research Institute division and doing business as Kaiser Permanente, is a non-profit integrated healthcare system and research organization that delivers health services research, clinical epidemiology, and vaccine safety surveillance to the federal government as a prime contractor and research recipient across 68 federal agencies. The vendor holds no SBA set-aside designations and competes full-and-open; it operates predominantly as a prime contractor (63% of awards) anchored in comprehensive electronic health records spanning 4.5 million diverse members across multiple Kaiser Permanente regional health plans including Northern California, Southern California, Northwest, Washington, and Hawaii.

Kaiser Permanente's federal footprint centers on three capability pillars: vaccine safety epidemiology and immunization safety assessment delivered to the CDC; evidence synthesis and systematic review services for healthcare policy agencies; and longitudinal epidemiological and clinical outcomes research on chronic disease, cancer, cardiovascular health, mental health, and health disparities funded by the National Institutes of Health. Recent contract work includes a $1.129 million definitive contract awarded September 25, 2026, by the National Institute of Child Health and Human Development for maintenance and analysis of the Kaiser Permanente Northern California Adult Alcohol Registry through March 2032 (cost-no-fee, research and development in physical, engineering, and life sciences under NAICS 541715); a $5.07 million delivery order from the CDC Pittsburgh for evaluating the childhood vaccination schedule under the Vaccine Safety Datalink IDIQ (firm fixed price through June 2028); and a $3.602 million firm fixed-price delivery order awarded September 29, 2025, by the Agency for Healthcare Research and Quality for systematic evidence reviews supporting the U.S. Preventive Services Task Force under the Evidence-based Practice Centers VII IDIQ. Grant work is substantial and growing: Kaiser serves as prime recipient on 931 awards spanning NIH institutes and centers, the CDC, FDA, and HHS agencies, with recent project grants including $10.492 million from the National Institute for Minority Health and Health Disparities for implementation science on racial and ethnic disparities in depression treatment outcomes across five health systems in seven states (recipient through March 31, 2026); $3.92 million from the National Heart, Lung, and Blood Institute for the HIDDEN-ASCVD study leveraging deep learning and opportunistic imaging for coronary artery calcium detection (through August 31, 2029); and $3.676 million from the National Institute of Environmental Health Sciences for wildfire and extreme heat exposure effects on autism spectrum disorder development in children (through August 17, 2030).

Customer concentration is highly skewed toward HHS components. The top five funding agencies—the CDC Pittsburgh, the National Cancer Institute, the National Heart Lung and Blood Institute, the National Institute on Aging, and the National Institute of Environmental Health Sciences—account for approximately 50% of recent awards by count. By potential value, the CDC Pittsburgh alone anchors $2.02 billion (72% of combined potential value across all awards), driven by Kaiser's dominant position on the Vaccine Safety Datalink project (60 task orders, $137.6 million combined ceiling) and the Vaccine Safety Datalink IDIQ (14 task orders, $102.2 million ceiling). The FDA accounts for $221.5 million (7.9% of combined potential value). This concentration reflects Kaiser Permanente's established infrastructure for longitudinal vaccine safety surveillance and real-world outcomes research grounded in its integrated health system and EHR.

Kaiser Permanente holds indefinite-delivery vehicles anchoring ongoing work: the Evidence-based Practice Centers VII IDIQ with AHRQ ($90 million ceiling through June 30, 2030, hosting two delivered orders totaling $4.052 million); the Clinical Immunization Safety Assessment IDIQ with the CDC ($86 million ceiling through September 2028); and the Coronary Artery Risk Development in Young Adults (CARDIA) Study Oakland Field Center with the National Heart Lung and Blood Institute ($11 million ceiling through June 30, 2034). Recent activity shows growth: 209 awards in 2024 and 208 in 2025, with 106 awards year-to-date in 2026. However, 104 awards (combined potential value $146.7 million) face ultimate completion within the next twenty-four months, representing recompete exposure and opportunity for competitors.

On federal services contracts captured in Service Contract Inventory (SCI) for FY2022–FY2025, Kaiser reported invoiced amounts of $173.8 million across 169 prime records, with FY2022 at $32.2 million (105 FTEs), FY2023 at $52.4 million (138 FTEs), FY2024 at $48.8 million (133 FTEs), and FY2025 at $40.4 million (114 FTEs). Government-paid hourly rates on SCI-reportable prime contracts ranged from a 10th percentile of $86.98/hr to a median of $161.39/hr, with senior labor reaching the 90th percentile of $439.75/hr. Kaiser operates primarily with its own delivery teams; across SCI-reportable prime contracts, subcontractors accounted for approximately 8% of total contractor hours, with 71 named subcontractors engaged over the period. In its subcontractor role, Kaiser serves as a research site and data-providing partner to academic and research institutions including Columbia University, Johns Hopkins University, Duke University, Stanford University, and the University of Washington on grants spanning cancer research, cardiovascular outcomes, substance use disorders, and health services research methodology. The vendor maintains no parent-subsidiary relationships affecting federal contracting posture; it operates as a division of Kaiser Foundation Health Plan, Inc., a non-profit parent.